https://idataresearch.com/wp-content/uploads/2016/04/ReportIcon-Cell-MS.jpg

Orthobiologics Market Analysis, Size, Trends | Australia | 2020-2026 | Medsuite

  • Year: 2020
  • Scope: 2016-2026
  • Region: Australia
  • Pages: 285
  • Published Date: 07/02/2020
  • Type: MedSuite

In 2020, the Australian orthobiologics market size was valued at $63.8 million, with over 29,000 bone grafting procedures performed every year. The market size is expected to increase at a compound annual growth rate (CAGR) of 4.9% to reach $89.4 million in 2026.

Throughout this medical market research, we analyzed 48 orthobiologics companies across Australia and used our comprehensive methodology to understand the market sizes, unit sales, company market shares, and to create accurate forecasts.

While this MedSuite report contains all of the Australian Orthopedic Biomaterials market data and analysis, each of the market segments is also available as stand-alone MedCore reports. This allows you to get access to only the market research that you need.

DATA TYPES INCLUDED

  • Unit Sales, Average Selling Prices, Market Value & Growth Trends
  • Forecasts Until 2026, and Historical Data to 2016
  • Market Drivers & Limiters for Each Orthopedic Biomaterials Device market
  • Competitive Analysis with Market Shares for Each Segment
  • Recent Mergers & Acquisitions
  • Orthobiologics Procedure Volumes
  • Disease Overviews and Demographic Information
  • Company Profiles, Product Portfolios and SWOT for Top Competitors
  • Related Press Releases from Top Competitors

Market Value and Industry Trends

With some exceptions, tissue supply for allografts and DBM allografts is constrained by the number of available donors. Furthermore, allografts are primarily sold by bone banks in Australia, which is attributed to a relatively high barrier to entry to the market for international companies. As the population ages, there will be a lower supply of eligible bone graft donors.

Australia Orthobiologics Market Size by Segment, 2016-2026

Surgical procedures that require the use of orthopedic biomaterials are generally associated with diseases and indications that become more prevalent in the population with an increase in age, such as osteoarthritis of the spine and knee. In 2019, over 15% of Australians were aged 65 and over; this proportion is projected to grow steadily over the forecast period, as further cohorts of baby boomers turn 65.

Single-injection HA viscosupplementation products are relatively new to the Australian market. In 2019, there were three single-injection products available: Sanofi’s Synvisc-One®, Bioventus’ Durolane® and Anika Therapeutics’ MONOVISC®. Although three-injection products were available in Australia before single-injection products, the benefits of the latter are typically perceived to outweigh the favorable cost of the former. As a result, single-injection products are expected to> continue to cannibalize three-injection products over the forecast period.

Competitive Analysis

Australia Orthopedic Biomaterials Market Leaders

By 2020, the leading competitor in the Australian orthopedic biomaterials market was Medtronic. The company has established this role through strong performance of its growth factor product line, INFUSE®, which first entered the market in 2006. Medtronic also held a notable position in the DBM allograft and synthetic markets.

DePuy Synthes was the second-leading competitor in the Australian market, which was solely attributed to its leading position in the orthopedic bone graft substitute market. The company was particularly strong in the DBM allograft market, which continues to be the fastest-growing bone graft substitute segment.

Other notable competitors included, but were not limited to, Stryker, bone banks, Wright Medical, Cerapedics, Sanofi, Bioventus and Anika Therapeutics. Unlike the bone graft substitute market, which is heavily fragmented, the orthopedic graft factor and HA viscosupplementation markets are controlled by a smaller number of companies.

Segments Covered

Click on each title to view more detailed market segmentation.

  • Procedure Volumes for Orthopedic Biomaterials DevicesMedPro – The Complete procedural analysis for each segment of the Australian Orthopedic Biomaterials market.
  • Orthopedic Bone Graft Substitute Market – MedCore – This market is further segmented by Material Type, including Allograft, Demineralized Bone Matrix Allograft, and Synthetic. Each of these Material Types are segmented by Spine, Trauma, Large Joint Reconstruction, Craniomaxillofacial, and Oncology.
  • Orthopedic Growth Factor Market – MedCore – In-depth analysis of the Orthopedic Growth Factor market.
  • Hyaluronic Acid Viscosupplementation Market – MedCore – This market is categorized by Treatment Type, including Single-Injection and Three-Injection.

Detailed Market Segmentation

DON’T SEE THE SEGMENT OR DATA YOU NEED?

Feel free to contact us or send a request by pressing one of the buttons below.

TABLE OF CONTENTS FOR THE AUSTRALIAN ORTHOPEDIC BIOMATERIALS MARKET REPORT SUITE

TABLE OF CONTENTS ILIST OF FIGURES VIIILIST OF CHARTS XVEXECUTIVE SUMMARY 1AUSTRALIAN ORTHOPEDIC BIOMATERIALS MARKET OVERVIEW 1COMPETITIVE ANALYSIS 3MARKET TRENDS 5MARKET DEVELOPMENTS 6PROCEDURE NUMBERS 7MARKETS INCLUDED 8KEY REPORT UPDATES 10VERSION HISTORY 10RESEARCH METHODOLOGY 11Step 1: Project Initiation & Team Selection 11Step 2: Prepare Data Systems and Perform Secondary Research 14Step 3: Preparation for Interviews & Questionnaire Design 16Step 4: Performing Primary Research 17Step 5: Research Analysis: Establishing Baseline Estimates 19Step 6: Market Forecast and Analysis 20Step 7: Identify Strategic Opportunities 22Step 8: Final Review and Market Release 23Step 9: Customer Feedback and Market Monitoring 24

PRODUCT ASSESSMENT

2.1 INTRODUCTION 252.2 PRODUCT PORTFOLIOS 252.2.1 Bone Graft Substitutes 262.2.2 Growth Factors 322.2.2.1 Other products 352.2.3 Hyaluronic Acid Viscosupplementation (HAV) 372.3 REGULATORY ISSUES AND RECALLS 402.3.1 Bone Graft Substitutes 402.3.1.1 Allografts 402.3.1.1.1 MTF 402.3.1.2 DBM 402.3.1.2.1 AlloSource 402.3.1.2.2 SeaSpine 412.3.1.2.3 RTI Surgical 412.3.1.3 Synthetics 412.3.1.3.1 Abyrx 412.3.1.3.2 Zimmer Biomet 422.3.2 Growth Factors 422.3.2.1.1 Medtronic 422.3.3 Hyaluronic Acid Viscosupplementation 432.3.3.1 Three-injection 432.3.3.1.1 Ferring Pharmaceuticals 432.4 CLINICAL TRIALS 442.4.1 Bone Graft Substitutes 442.4.1.1 Allografts 442.4.1.1.1 Providence Medical Technology 442.4.1.1.2 The University of Texas Health Science 442.4.1.1.3 University of Winchester 452.4.1.2 BDM 452.4.1.2.1 K2M 452.4.1.2.2 Zimmer Biomet 462.4.1.3 Synthetics 462.4.1.3.1 Baxter 462.4.1.3.2 Bonesupport 472.4.1.3.3 DePuy Synthes 472.4.1.3.4 NuVasive 492.4.1.3.5 RTI surgical 492.4.1.3.6 Sunstar GUIDOR 502.4.1.4 Other materials and comparison 512.4.1.4.1 Seoul National University Hospital. 512.4.1.4.2 Sewon Cellontech 512.4.1.4.3 SurgaColl Technologies Limited 522.4.1.4.4 University of Colorado 522.4.1.4.5 University of Padova 532.4.2 Growth Factors 532.4.2.1.1 Bioventus 532.4.2.1.2 Cerapedics 542.4.2.1.3 CGBio 542.4.2.1.4 Isto 552.4.2.1.5 Medtronic 552.4.2.1.6 NuVasive 572.4.2.1.7 Wright 572.4.2.1.8 Others 582.4.3 Hyaluronic Acid Viscosupplementation 592.4.3.1.1 Anika Therapeutics 592.4.3.1.2 Bioventus 602.4.3.1.3 Cario University 612.4.3.1.4 Ferring Pharmaceuticals 612.4.3.1.5 Federal University of Minas Gerais 622.4.3.1.6 Fidia Pharma USA Inc. 622.4.3.1.7 Istituto Ortopedico Rizzoli 632.4.3.1.8 University Hospital 632.4.3.1.9 Universidade Nova de Lisboa 64

AUSTRALIAN ORTHOPEDIC BIOMATERIALS MARKET OVERVIEW

3.1 INTRODUCTION 653.1.1 Bone Graft Substitutes 653.1.2 Growth Factors 653.1.3 Hyaluronic Acid (HA) Viscosupplementation 663.2 CURRENCY EXCHANGE RATE 673.3 MARKET OVERVIEW AND TREND ANALYSIS 683.4 DRIVERS AND LIMITERS 763.4.1 Market Drivers 763.4.2 Market Limiters 763.5 COMPETITIVE MARKET SHARE ANALYSIS 783.6 MERGERS AND ACQUISITIONS 843.7 COMPANY PROFILES 863.7.1 Anika Therapeutics 863.7.2 Bioventus 873.7.3 DePuy Synthes 883.7.4 Ferring Pharmaceuticals 893.7.5 Fidia Pharmaceuticals 903.7.6 Genzyme (Sanofi Group) 913.7.7 Harvest Technologies (Terumo BCT) 923.7.8 Integra LifeSciences 933.7.9 Medtronic 943.7.10 Musculoskeletal Transplant Foundation (MTF) 963.7.11 NuVasive 973.7.12 Orthofix 983.7.13 RTI Surgical 993.7.14 Stryker 1003.7.15 Vericel Corporation (formerly Aastrom Bioscience) 1013.7.16 Zimmer Biomet 1023.8 SWOT ANALYSIS 1043.8.1 Anika Therapeutics 1043.8.2 Bioventus 1063.8.3 DePuy Synthes 1083.8.4 Ferring Pharmaceuticals 1093.8.5 Fidia Pharmaceuticals 1103.8.7 Harvest Technologies (Terumo BCT) 1123.8.8 Integra LifeSciences 1133.8.9 Medtronic 1143.8.10 Musculoskeletal Transplant Foundation (MTF) 1153.8.11 NuVasive 1163.8.12 Orthofix 1173.8.14 Stryker 1193.8.15 Vericel Corporation (formerly Aastrom Bioscience) 1203.8.16 Zimmer Biomet 121

PROCEDURE NUMBERS

4.1 INTRODUCTION 1234.2 PROCEDURES 1244.2.1 Orthopedic Biomaterial Procedures by Segment 1244.2.2 Orthopedic Bone Grafting Procedures 1264.2.2.1 Units per Procedure by Indication 1264.2.2.2 Orthopedic Bone Grafting Procedures by Material 1274.2.2.2.1 Autograft Procedures by Indication 1294.2.2.2.2 Allograft Procedures by Indication 1324.2.2.2.3 DBM Allograft Procedures by Indication 1354.2.2.2.4 Synthetic Procedures by Indication 1384.2.2.3 Orthopedic Bone Grafting Procedures by Indication 1414.2.3 Orthopedic Growth Factor Procedures 1444.2.4 Hyaluronic Acid Supplementation Procedures 1464.2.4.1 Hyaluronic Acid Supplementation Procedures by Injection Cycle 146

ORTHOPEDIC BONE GRAFT SUBSTITUTE MARKET

5.1 INTRODUCTION 1485.2 MARKET OVERVIEW 1495.2.1 Orthopedic Bone Graft Substitute Market by Material 1495.2.2 Orthopedic Bone Graft Substitute Market by Indication 1545.3 MARKET ANALYSIS AND FORECAST 1605.3.1 Total Orthopedic Bone Graft Substitute Market 1605.3.2 Orthopedic Bone Graft Substitute Market by Material 1625.3.2.1 Allograft Bone Graft Substitute Market 1625.3.2.1.1 Allograft Bone Graft Substitute Market by Indication 1645.3.2.2 Demineralized Bone Matrix Allograft Bone Graft Substitute Market 1785.3.2.2.1 Demineralized Bone Matrix Allograft Bone Graft Substitute Market by Indication 1805.3.2.3 Synthetic Bone Graft Substitute Market 1945.3.2.3.1 Synthetic Bone Graft Substitute Market by Indication 1965.3.3 Orthopedic Bone Graft Substitute Market by Indication 2105.3.3.1 Spine Bone Graft Substitute Market 2105.3.3.2 Cervical Spine Bone Graft Substitute Market 2125.3.3.3 Thoracolumbar Spine Bone Graft Substitute Market 2145.3.3.4 Trauma Bone Graft Substitute Market 2165.3.3.5 Non-Union Trauma Bone Graft Substitute Market 2185.3.3.6 Fresh Fracture Trauma Bone Graft Substitute Market 2205.3.3.7 Large Joint Reconstruction Bone Graft Substitute Market 2225.3.3.8 Hip Reconstruction Bone Graft Substitute Market 2245.3.3.9 Knee Reconstruction Bone Graft Substitute Market 2265.3.3.10 Foot Reconstruction Bone Graft Substitute Market 2285.3.3.11 Craniomaxillofacial Bone Graft Substitute Market 2305.3.3.12 Oncology Bone Graft Substitute Market 2325.4 DRIVERS AND LIMITERS 2345.4.1 Market Drivers 2345.4.2 Market Limiters 2345.5 COMPETITIVE MARKET SHARE ANALYSIS 236

ORTHOPEDIC GROWTH FACTOR MARKET

6.1 INTRODUCTION 2406.1.1 BMP-2 (Medtronic) 2416.1.2 PDGF-BB (Wright Medical) 2416.1.3 P-15 Synthetic Small Peptide (Cerapedics) 2416.1.4 P-15 Synthetic Small Peptide (Biocomposites) 2416.2 MARKET ANALYSIS AND FORECAST 2426.3 DRIVERS AND LIMITERS 2446.3.1 Market Drivers 2446.3.2 Market Limiters 2446.4 COMPETITIVE MARKET SHARE ANALYSIS 246

HYALURONIC ACID VISCOSUPPLEMENTATION MARKET

7.1 INTRODUCTION 2497.1.1 Benefits of Viscosupplementation 2507.1.2 Synovial Fluid 2507.2 MARKET OVERVIEW 2517.3 MARKET ANALYSIS AND FORECAST 2577.3.1 Total Hyaluronic Acid Viscosupplementation Market 2577.3.2 Single-Injection Hyaluronic Acid Viscosupplementation Market 2597.3.3 Three-Injection Hyaluronic Acid Viscosupplementation Market 2617.4 DRIVERS AND LIMITERS 2637.4.1 Market Drivers 2637.4.2 Market Limiters 2637.5 COMPETITIVE MARKET SHARE ANALYSIS 265

ABBREVIATIONS

The Orthobiologics Market Report Suite | Australia | 2020-2026 | MedSuite includes analysis on the following companies currently active in this market:
  • Alphatec
  • Anika Therapeutics
  • Arthrex
  • Australian Biotechnologies
  • Australian Tissue Donation Network
  • B. Braun
  • Barwon Health Bone Bank
  • Baxter
  • Biocomposites
  • Bioventus
  • Cerapedics
  • Corin
  • DePuy Synthes
  • Donor Tissue Bank of Victoria
  • Finceramica
  • Globus Medical
  • Hunter New England and Local Health District
  • Hunter New England Bone Bank
  • Institute of Medical & Veterinary Science
  • Joy Surgical
  • JRI Orthopaedics
  • Kasios
  • LifeHealthcare
  • LMT Surgical
  • Alphatec
  • Anika Therapeutics
  • Arthrex
  • Australian Biotechnologies
  • Australian Tissue Donation Network
  • B. Braun
  • Barwon Health Bone Bank
  • Baxter
  • Biocomposites
  • Bioventus
  • Cerapedics
  • Corin
  • DePuy Synthes
  • Donor Tissue Bank of Victoria
  • Finceramica
  • Globus Medical
  • Hunter New England and Local Health District
  • Hunter New England Bone Bank
  • Institute of Medical & Veterinary Science
  • Joy Surgical
  • JRI Orthopaedics
  • Kasios
  • LifeHealthcare
  • LMT Surgical

iData’s 9-Step Research Methodology

Our reports follow an in-depth 9-step methodology which focuses on the following research systems:

  • Original primary research that consists of the most up-to-date market data
  • Strong foundation of quantitative and qualitative research
  • Focused on the needs and strategic challenges of the industry participants

Step 1: Project Initiation & Team Selection During this preliminary investigation, all staff members involved in the industry discusses the topic in detail.

Step 2: Prepare Data Systems and Perform Secondary Research The first task of the research team is to prepare for the data collection process: Filing systems and relational databases are developed as needed.

Step 3: Preparation for Interviews & Questionnaire Design The core of all iData research reports is primary market research. Interviews with industry insiders represent the single most reliable way to obtain accurate, current data about market conditions, trends, threats and opportunities.

Step 4: Performing Primary Research At this stage, interviews are performed using contacts and information acquired in the secondary research phase.

Step 5: Research Analysis: Establishing Baseline Estimates Following the completion of the primary research phase, the collected information must be synthesized into an accurate view of the market status. The most important question is the current state of the market.

Step 6: Market Forecast and Analysis iData Research uses a proprietary method to combine statistical data and opinions of industry experts to forecast future market values.

Step 7: Identify Strategic Opportunities iData analysts identify in broad terms why some companies are gaining or losing share within a given market segment.

Step 8: Final Review and Market Release An integral part of the iData research methodology is a built-in philosophy of quality control and continuing improvement is integral to the iData philosophy.

Step 9: Customer Feedback and Market Monitoring iData philosophy of continuous improvement requires that reports and consulting projects be monitored after release for customer feedback and market accuracy.

Click Here to Read More About Our Methodology